Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity.

The effects of a nonselective beta-adrenergic blocking agent with (pindolol) and without (propranolol) intrinsic sympathomimetic activity properties, compared with placebo-controlled conditions, on metabolic and cardiorespiratory function during long-duration (2 hours) physical activity were examined. After initial cardiorespiratory testing, subjects performed 2-hour walks at 25 and 45% of maximal oxygen consumption (VO2max) under each of the following 3 treatments: pindolol, propranolol and placebo. Medication distribution was randomized and double-blinded. A supine resting blood pressure and electrocardiogram were obtained before each exercise trial. Oxygen consumption, heart rate, stroke volume, cardiac output and blood pressure were determined after 5 minutes of quiet sitting and every 30 minutes during each 2-hour exercise trial. Cardiac output was not significantly different at rest or during exercise, comparing pindolol and propranolol with placebo conditions. Cardiac output tended to decrease over time earlier during propranolol treatment for the 25% VO2max trials in trained normotensive subjects than for the other treatments. Cardiac output decreased at approximately the same time across treatments during the 45% VO2max trials in trained normotensive and untrained hypertensive groups. Finally, owing to the observation that a reduction in cardiac output was delayed or prevented in trained normotensive subjects when compared with that in untrained hypertensives while exercising at 25% VO2max, developing a subject's cardiovascular fitness level may be important in the maintenance of cardiac output during extended periods of low-to-moderate physical activities while under the influence of beta-adrenergic blockade.

Stroke volume during submaximal exercise in endurance-trained normotensive subjects and in untrained hypertensive subjects with beta blockade (propranolol and pindolol).

The effect of beta-adrenergic blockade on stroke volume (SV) at increasing submaximal exercise intensities was studied in 12 endurance-trained normotensive and 12 untrained hypertensive (diastolic blood pressure greater than 95 mm Hg) men, aged 18 to 34 years. Subjects were assigned to each of 3 treatments in a double-blind, randomized order: placebo, propranolol (80 mg twice daily) and pindolol (10 mg twice daily) for 10 days, with a period of 48 to 60 hours from the initial dose to the first treadmill test and a 4-day washout period between drugs. Cardiac output was measured using the carbon dioxide rebreathing method and SV was calculated from cardiac output and heart rate as follows: SV = cardiac output/heart rate. Cardiac outputs were estimated at rest and while walking on a treadmill at 25, 45, 60 and 75% of the subject's previously determined maximal oxygen uptake (VO2max). No significant differences were found in cardiac output between either of the drugs and placebo at rest, or at any of the 4 rates of work. Propranolol significantly increased SV above placebo values (p less than 0.05) for both trained and untrained groups at the intensities of 45, 60 and 75%. Significant differences in SV were found between pindolol and placebo only at the intensities of 60 and 75% in the trained group. Contrary to expectations, SV showed no indication of a plateau with propranolol in the trained subjects throughout the 4 different exercise intensities, whereas a plateau was established under placebo conditions by 45% of VO2max in both trained and untrained subjects. These results suggest that both trained and untrained hypertensive persons can exercise with beta-adrenergic blockade at submaximal levels without compromised cardiac function.

Comparison of the effects of pindolol and propranolol on exercise performance in young men with systemic hypertension.

To determine the effect of intrinsic sympathomimetic activity (ISA) on exercise performance during beta blockade, 12 hypertensive men were studied. The subjects underwent graded treadmill testing while taking pindolol (a beta blocker with ISA), propranolol (a beta blocker without ISA) and placebo, in a double-blind, crossover fashion. Blood pressure, heart rate, oxygen consumption (VO2), cardiac output and stroke volume were determined at 25, 45, 60 and 75% of each subject's VO2 max. Heart rate was significantly lower with pindolol compared with placebo at all stages of exercise, but significantly higher compared with propranolol at all stages of exercise except at 75% of VO2 max and at VO2 max (no significant differences between the 2 beta blockers were recorded at these stages). Mean arterial pressure was statistically equivalent with pindolol and propranolol at all stages of exercise and significantly lower while beta-blocked compared with placebo conditions at 45, 60 and 75% of VO2 max. Cardiac output and VO2 were statistically equivalent across all 3 treatments at all submaximal levels of exercise. It was concluded that, although heart rate was significantly higher with pindolol compared with propranolol at the 3 lower rates of work, cardiac output and VO2 were not different between the drugs, thus making little impact on exercise performance.